1.000000 0.000000 0.000000 0.000000 1.000000 0.000000 0.000000 0.000000 1.000000 0.00000 0.00000 0.00000 Bocian, W. Kozerski, L. http://mmcif.pdb.org/dictionaries/ascii/mmcif_pdbx.dic C3 H7 N O2 89.093 y ALANINE L-peptide linking C6 H15 N4 O2 1 175.209 y ARGININE L-peptide linking C4 H8 N2 O3 132.118 y ASPARAGINE L-peptide linking C3 H7 N O2 S 121.158 y CYSTEINE L-peptide linking C5 H10 N2 O3 146.144 y GLUTAMINE L-peptide linking C5 H9 N O4 147.129 y GLUTAMIC ACID L-peptide linking C2 H5 N O2 75.067 y GLYCINE peptide linking C6 H10 N3 O2 1 156.162 y HISTIDINE L-peptide linking C6 H13 N O2 131.173 y ISOLEUCINE L-peptide linking C6 H13 N O2 131.173 y LEUCINE L-peptide linking C6 H15 N2 O2 1 147.195 y LYSINE L-peptide linking C9 H11 N O2 165.189 y PHENYLALANINE L-peptide linking C5 H9 N O2 115.130 y PROLINE L-peptide linking C3 H7 N O3 105.093 y SERINE L-peptide linking C4 H9 N O3 119.119 y THREONINE L-peptide linking C9 H11 N O3 181.189 y TYROSINE L-peptide linking C5 H11 N O2 117.146 y VALINE L-peptide linking NE J.Biomol.Nmr JBNME9 0800 0925-2738 55 303 309 10.1007/s10858-013-9713-2 23404086 Biosynthetic engineered B28(K)-B29(P) human insulin monomer structure in water and in water/acetonitrile solutions. 2013 2383.698 Insulin 1 syn polymer 3433.953 Insulin P28K, K29P 1 syn polymer Insulin B chain, Insulin A chain Insulin B chain, Insulin A chain no no GIVEQCCTSICSLYQLENYCN GIVEQCCTSICSLYQLENYCN A polypeptide(L) no no FVNQHLCGSHLVEALYLVCGERGFFYTKPT FVNQHLCGSHLVEALYLVCGERGFFYTKPT B polypeptide(L) n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n n human sample INS 9606 Homo sapiens human sample INS 9606 Homo sapiens repository Initial release Database references 1 0 2013-02-27 1 1 2013-05-22 BMRB Y RCSB 2012-11-26 REL REL REL structures with the lowest energy 100 20 2D 1H-1H TOCSY 2D 1H-1H NOESY 2D 1H-1H NOESY 2D 1H-13C HSQC 2.5-3.0 mM 2.5-3.0 mM 73 % 27 % 2.5-3.0 mM 2.5-3.0 mM 73 % 27 % 1 2.5 ambient 298 K torsion angle dynamics, DGSA-distance geometry simulated annealing 1 fewest violations 2.5 - 3.0 mM insulin, residues 90-110, 2.5 - 3.0 mM insulin, residues 25-54, 73 % H2O, 27 % CD3CN, H2O / CD3CN H2O / CD3CN 2.5 - 3.0 mM insulin, residues 90-110, 2.5 - 3.0 mM insulin, residues 25-54, 73 % D2O-7, 27 % CD3CN-8, D2O / CD3CN D2O / CD3CN Case, Darden, Cheatham, III, Simmerling, Wang, Duke, Luo, and Kollman refinement AMBER 11 Case, Darden, Cheatham, III, Simmerling, Wang, Duke, Luo, and Kollman structure solution AMBER 11 Guntert, Mumenthaler and Wuthrich refinement CYANA 2.1 Varian collection VNMRJ 2.2 C Goddard chemical shift assignment SPARKY 2.6 500 Varian Uniform NMR System Varian Uniform NMR System GLY 1 n 1 GLY 1 A ILE 2 n 2 ILE 2 A VAL 3 n 3 VAL 3 A GLU 4 n 4 GLU 4 A GLN 5 n 5 GLN 5 A CYS 6 n 6 CYS 6 A CYS 7 n 7 CYS 7 A THR 8 n 8 THR 8 A SER 9 n 9 SER 9 A ILE 10 n 10 ILE 10 A CYS 11 n 11 CYS 11 A SER 12 n 12 SER 12 A LEU 13 n 13 LEU 13 A TYR 14 n 14 TYR 14 A GLN 15 n 15 GLN 15 A LEU 16 n 16 LEU 16 A GLU 17 n 17 GLU 17 A ASN 18 n 18 ASN 18 A TYR 19 n 19 TYR 19 A CYS 20 n 20 CYS 20 A ASN 21 n 21 ASN 21 A PHE 1 n 1 PHE 1 B VAL 2 n 2 VAL 2 B ASN 3 n 3 ASN 3 B GLN 4 n 4 GLN 4 B HIS 5 n 5 HIS 5 B LEU 6 n 6 LEU 6 B CYS 7 n 7 CYS 7 B GLY 8 n 8 GLY 8 B SER 9 n 9 SER 9 B HIS 10 n 10 HIS 10 B LEU 11 n 11 LEU 11 B VAL 12 n 12 VAL 12 B GLU 13 n 13 GLU 13 B ALA 14 n 14 ALA 14 B LEU 15 n 15 LEU 15 B TYR 16 n 16 TYR 16 B LEU 17 n 17 LEU 17 B VAL 18 n 18 VAL 18 B CYS 19 n 19 CYS 19 B GLY 20 n 20 GLY 20 B GLU 21 n 21 GLU 21 B ARG 22 n 22 ARG 22 B GLY 23 n 23 GLY 23 B PHE 24 n 24 PHE 24 B PHE 25 n 25 PHE 25 B TYR 26 n 26 TYR 26 B THR 27 n 27 THR 27 B LYS 28 n 28 LYS 28 B PRO 29 n 29 PRO 29 B THR 30 n 30 THR 30 B author_defined_assembly 2 dimeric 1.0000000000 0.0000000000 0.0000000000 0.0000000000 1.0000000000 0.0000000000 0.0000000000 0.0000000000 1.0000000000 1_555 x,y,z identity operation 0.0000000000 0.0000000000 0.0000000000 1 3.39 0.50 120.30 123.69 B B B NE CZ NH1 ARG ARG ARG 22 22 22 N 5 3.00 0.50 120.30 123.30 B B B NE CZ NH1 ARG ARG ARG 22 22 22 N 10 3.21 0.50 120.30 123.51 B B B NE CZ NH1 ARG ARG ARG 22 22 22 N 12 3.32 0.50 120.30 123.62 B B B NE CZ NH1 ARG ARG ARG 22 22 22 N 13 -3.99 0.60 121.00 117.01 B B B CB CG CD2 TYR TYR TYR 26 26 26 N 14 3.28 0.50 120.30 123.58 B B B NE CZ NH1 ARG ARG ARG 22 22 22 N 1 B LYS 28 37.71 56.04 2 B ASN 3 -118.99 70.83 3 B TYR 26 -84.58 31.41 5 B GLU 21 -159.99 -10.79 6 B VAL 2 51.69 -46.89 6 B PHE 25 -141.62 -32.63 6 B TYR 26 54.84 134.24 7 B PHE 24 -139.91 -54.77 8 B VAL 2 -143.11 -38.66 8 B GLN 4 65.45 157.84 9 B ASN 3 -150.75 38.35 9 B TYR 26 49.58 19.72 10 B THR 27 57.87 -14.32 12 B PHE 25 -139.11 -35.82 12 B TYR 26 47.80 -81.63 13 B THR 27 56.17 -46.19 13 B LYS 28 61.82 152.79 14 B GLU 21 54.08 19.61 14 B THR 27 53.03 -114.92 15 A GLN 5 -123.21 -57.16 15 B PHE 24 -150.67 -43.21 16 B PHE 25 -140.73 -26.32 16 B TYR 26 46.83 -97.97 18 B PHE 24 -136.15 -52.70 18 B THR 27 58.61 7.74 18 B LYS 28 32.86 60.63 20 B PHE 24 -134.83 -78.57 20 B PHE 25 49.82 71.86 Insulin fewest violations, model 1 Biosynthetic engineered B28K-B29P human insulin monomer structure in in water/acetonitrile solutions. 1 N N 2 N N A GLY 1 A GLY 1 HELX_P A CYS 7 A CYS 7 1 1 7 A SER 12 A SER 12 HELX_P A GLU 17 A GLU 17 1 2 6 A ASN 18 A ASN 18 HELX_P A CYS 20 A CYS 20 5 3 3 B GLY 8 B GLY 8 HELX_P B GLY 20 B GLY 20 1 4 13 disulf 2.034 A CYS 6 A SG CYS 6 1_555 A CYS 11 A SG CYS 11 1_555 disulf 2.037 A CYS 7 A SG CYS 7 1_555 B CYS 7 B SG CYS 7 1_555 disulf 2.030 A CYS 20 A SG CYS 20 1_555 B CYS 19 B SG CYS 19 1_555 HORMONE Human Insulin, Hormone INS_HUMAN UNP 1 90 P01308 GIVEQCCTSICSLYQLENYCN INS_HUMAN UNP 2 25 P01308 FVNQHLCGSHLVEALYLVCGERGFFYTPKT 90 110 2M1D 1 21 P01308 A 1 1 21 25 54 2M1D 1 30 P01308 B 2 1 30 2 PRO ENGINEERED MUTATION LYS 28 2M1D B P01308 UNP 52 28 2 LYS ENGINEERED MUTATION PRO 29 2M1D B P01308 UNP 53 29